The Beijing Key Laboratory of Polymorphic Drugs is the first key laboratory in China to engage in drug polymorphic research based on the drug polymorphic research center of Institute of Materia Medica, Chinese Academy of Medical Sciences and relied on the first class discipline of pharmacy of the Ministry of Education. The laboratory got the qualification certification in 2012, and gained excellent evaluation results in two consecutive rounds performance appraisal in 2015 and 2018 respectively.
The key laboratory is devoted to the international frontier research and national urgent technological demands, and occupied an important leading position in the field of polymorphic drug research in China. The laboratory consists of 41 permanent faculties and staffs and nearly 50 postgraduates, among whom 9 are professors, 17 are associate professors, 5 are Ph. D. supervisors and 15 are M. Sc. supervisors.
The laboratory has made enormous efforts in polymorphic drugs development. The researchers have presided over and undertaken a number of national and provincial/ministerial programs. It has trained more than 40 masters and doctors; applied for more than 120 patents, of which more than 60 have been granted. In addition, it has presided over the development of 212 national standards, and obtained the national standard material certificate. The laboratory successfully developed 7 Class I innovative polymorphic drugs, of which 5 have entered phase II clinical trials, and 2 have entered phase I clinical trials.
The laboratory has established an international research and development platform for polymorphic drugs, striving to advance current polymorphic drugs and develop novel technologies that can lead the development direction, improving the quality and standards, and promoting the consistency of polymorphic drugs in China. It aims at providing a high-level, high-quality academic and technical service platform with world-class facilities for innovative research of new polymorphic drugs.
